Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
AZD0486 / AstraZeneca
SOUNDTRACK-F1, NCT06549595: A Study of AZD0486 Plus Rituximab in Previously Untreated Follicular Lymphoma Patients	Recruiting	3	1015	Europe, Canada, Japan, RoW	AZD0486, R-CHOP, R-CVP, BR	AstraZeneca	Untreated Follicular Lymphoma	11/31	11/31
SOUNDTRACK-B, NCT06526793: AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL	Recruiting	2	240	Europe, Canada, Japan, US, RoW	AZD0486	AstraZeneca	B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL)	03/27	06/29
SYRUS, NCT06137118: AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia	Recruiting	1/2	120	Europe, Canada, Japan, US, RoW	AZD0486	AstraZeneca	B-cell Acute Lymphoblastic Leukemia (B-ALL)	07/26	05/27
Soundtrack-E, NCT06564038: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies	Recruiting	1/2	180	Europe, Japan, US, RoW	AZD0486, TNB-486, Acalabrutinib, Prednisone, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin	AstraZeneca	Chronic Lymphocytic Leukaemia, Small Lymphocytic Leukaemia, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma	04/31	04/31
D7400C00006, NCT04594642: A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma	Recruiting	1	317	Japan, US, RoW	AZD0486 IV, TNB-486	AstraZeneca	B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma	04/28	04/28
TNB-738 / TeneoFour, Inc, Ancora Biotech
NCT05215912: A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers	Completed	1	31	RoW	TNB-738	TeneoFour Inc., Novotech (Australia) Pty Limited	Healthy Volunteer	05/23	07/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
AZD0486 / AstraZeneca
SOUNDTRACK-F1, NCT06549595: A Study of AZD0486 Plus Rituximab in Previously Untreated Follicular Lymphoma Patients	Recruiting	3	1015	Europe, Canada, Japan, RoW	AZD0486, R-CHOP, R-CVP, BR	AstraZeneca	Untreated Follicular Lymphoma	11/31	11/31
SOUNDTRACK-B, NCT06526793: AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL	Recruiting	2	240	Europe, Canada, Japan, US, RoW	AZD0486	AstraZeneca	B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL)	03/27	06/29
SYRUS, NCT06137118: AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia	Recruiting	1/2	120	Europe, Canada, Japan, US, RoW	AZD0486	AstraZeneca	B-cell Acute Lymphoblastic Leukemia (B-ALL)	07/26	05/27
Soundtrack-E, NCT06564038: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies	Recruiting	1/2	180	Europe, Japan, US, RoW	AZD0486, TNB-486, Acalabrutinib, Prednisone, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin	AstraZeneca	Chronic Lymphocytic Leukaemia, Small Lymphocytic Leukaemia, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma	04/31	04/31
D7400C00006, NCT04594642: A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma	Recruiting	1	317	Japan, US, RoW	AZD0486 IV, TNB-486	AstraZeneca	B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma	04/28	04/28
TNB-738 / TeneoFour, Inc, Ancora Biotech
NCT05215912: A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers	Completed	1	31	RoW	TNB-738	TeneoFour Inc., Novotech (Australia) Pty Limited	Healthy Volunteer	05/23	07/23